Cytochrome P450 2D6 (CYP 450 2D6) Genotype and Flecainide Efficacy
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00945867 |
Recruitment Status
: Unknown
Verified July 2009 by Assaf-Harofeh Medical Center.
Recruitment status was: Not yet recruiting
First Posted
: July 24, 2009
Last Update Posted
: April 5, 2011
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Atrial Fibrillation |
Study Type : | Observational |
Estimated Enrollment : | 100 participants |
Observational Model: | Case-Only |
Time Perspective: | Prospective |
Official Title: | The Use of CYP 450 2D6 Genotype as a Predictor of Flecainide Efficacy in the Treatment of Patients With Atrial Fibrillation |
Study Start Date : | September 2009 |
Estimated Primary Completion Date : | March 2010 |
Estimated Study Completion Date : | August 2010 |

- no recurrence of atrial fibrillation [ Time Frame: 3 months ]
- the dose of flecainide used [ Time Frame: 6 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 90 Years (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Patients with recurrent AF
- Patients with a structurally normal heart
- Patients > 18 YO
- Patients who signed an informed consent
Exclusion Criteria:
- Renal failure with creatinine clearance less than 40
- Elevated liver enzymes 3 times the normal range, or causing coagulation test abnormality
- Pregnant patients
- Patients treated with psychiatric agents

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00945867
Contact: Therese Fuchs, MD | 972-8-977-8179 | fuchst@asaf.health.gov.il |
Israel | |
Assaf Harofeh Medical Center | Not yet recruiting |
Zrifin, Israel, 00000 | |
Contact: Therese Fuchs, MD 972-8-977-8179 fuchst@asaf.health.gov.il | |
Sub-Investigator: Moshe Sharist, MD |
Study Chair: | Moshe Sharist, MD | Assaf-Harofeh Medical Center | |
Study Chair: | Shmuel Bar-Haim, MD | Assaf-Harofeh Medical Center |
Responsible Party: | Therese Fuchs, MD, Assaf Harofeh Medical Center |
ClinicalTrials.gov Identifier: | NCT00945867 History of Changes |
Other Study ID Numbers: |
111/09 |
First Posted: | July 24, 2009 Key Record Dates |
Last Update Posted: | April 5, 2011 |
Last Verified: | July 2009 |
Keywords provided by Assaf-Harofeh Medical Center:
flecainide pharmacogenetics |
Additional relevant MeSH terms:
Atrial Fibrillation Arrhythmias, Cardiac Heart Diseases Cardiovascular Diseases Pathologic Processes Flecainide |
Anti-Arrhythmia Agents Voltage-Gated Sodium Channel Blockers Sodium Channel Blockers Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action |